Receiving a pulmonary fibrosis diagnosis is a life-changing event. Accepting this new reality may initially seem impossible. There are so many new things to consider that never were on the radar before they suddenly became important. In addition to finding your footing in the present, you must…
Embracing Caregiving: Learning to Accept a Diagnosis
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, exercising a licensing option under an earlier research partnership between the companies. Integrins control a wide variety of cellular processes, including…
At some point in everyone’s lives, we feel overwhelmed by the pressure to perform, whether it’s getting good grades at school, excelling at playing an instrument, or receiving a promotion at work. Many of these are normal pressures one expects throughout their lives. However, patients with idiopathic pulmonary fibrosis (IPF),…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the search for new medicines for rare disorders and incorporating more patient input into research. The goal is to help the pharmaceutical industry deliver innovative new therapies faster and smarter, the…
Four years of monitoring clinical use of Ofev (nintedanib) by people with idiopathic pulmonary fibrosis (IPF) has found no new safety concerns, a database study found. Treatment safety and tolerability were consistent with findings reported in pivotal trials, with non-severe diarrhea continuing to be the most common side effect noted,…
People with idiopathic pulmonary fibrosis (IPF) who are treated with either Ofev (nintedanib) or Esbriet (pirfenidone) report similar satisfaction with their medications, a new study suggests. The study, “Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study,”…
NXP004, Nuformix’s potential anti-fibrotic treatment for idiopathic pulmonary fibrosis (IPF), led to a dose-dependent reduction in the production and deposition of proteins that are known key drivers of fibrosis (tissue scarring) and IPF progression, a preclinical study shows. Although these are preliminary findings in a tissue study,…
Adelmidrol therapy reduced markers for inflammation and oxidative stress, as well as tissue damage and collagen deposits, in the lungs of mice with pulmonary fibrosis (PF), a study has found. The findings support further investigation of adelmidrol as a…
The EveryLife Foundation for Rare Diseases has launched a scholarship fund in the U.S. to support individuals with rare disorders who are pursuing personal goals through training and education. The initial phase of the five-year, $1-million #RAREis Scholarship Fund will include 32 scholarships — each totaling $5,000 —…
The world must learn to address our widespread anxiety about the ongoing health crisis. As a patient living with idiopathic pulmonary fibrosis (IPF), a life-threatening lung disease that makes me increasingly vulnerable to respiratory infections, I’m familiar with this anxiety. But life must continue, and it’s necessary to find a…
